Collectively, these results suggested that MAP2K2 expression regulated activation of the MEK/ERK pathway, which, in turn, influenced VEGFRi sensitivity in ccRCC cells. The gene discussed is MAP2K2; the disease is nonpapillary renal cell carcinoma.